The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
The PI3K Pathway As Drug Target in Human Cancer
Open accessAbstract
The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metabolism. This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components. In addition, PI3K signaling may serve integral functions for noncancerous cells in the tumor microenvironment. Consequently, therapeutics targeting the PI3K pathway are being developed at a rapid pace, and preclinical and early clinical studies are beginning to suggest specific strategies to effectively use them. However, the central role of PI3K signaling in a large array of diverse biologic processes raises concerns about its use in therapeutics and increases the need to develop sophisticated strategies for its use. In this review, we will discuss how PI3K signaling affects the growth and survival of tumor cells. From this vantage, we will consider how inhibitors of the PI3K signaling cascade, either alone or in combination with other therapeutics, can most effectively be used for the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
RetractedPhosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Self-citationAlessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., & Birnbaum, M. J. (2001) · Science · doi:10.1126/science.292.5522.1728 · Cited by 1,836
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Self-citationA transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
The lipid phosphatase activity of PTEN is critical for its tumor supressor function
Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13513 · Cited by 1,168
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
The PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Junttila, T. T., Akita, R. W., Parsons, K., Fields, C., Lewis Phillips, G. D., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829
Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L., & Roberts, T. M. (1985) · Nature · doi:10.1038/315239a0 · Cited by 810
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
Kaplan, D. R., Whitman, M., Schaffhausen, B., Pallas, D. C., White, M., Cantley, L., & Roberts, T. M. (1987) · Cell · doi:10.1016/0092-8674(87)90168-1 · Cited by 646
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes
Hresko, R. C., & Mueckler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 635
Skolnik, E. Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., & Schlessinger, J. (1991) · Cell · doi:10.1016/0092-8674(91)90410-z · Cited by 627
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Class I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
The Pharmacology of mTOR Inhibition
Guertin, D. A., & Sabatini, D. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe24 · Cited by 568
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 555
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 528
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Self-citationEichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., & Stokoe, D. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00493-9 · Cited by 477
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
Sugimoto, Y., Whitman, M., Cantley, L. C., & Erikson, R. L. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.7.2117 · Cited by 462
Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 456
Self-citationPIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L. (2007) · Science · doi:10.1126/science.1135394 · Cited by 410
The life of a cell: apoptosis regulation by the PI3K/PKB pathway
Duronio, V. (2008) · Biochemical Journal · doi:10.1042/bj20081056 · Cited by 390
Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S., & Cantley, L. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98375-4 · Cited by 388
Currie, R. A., Walker, K. S., Alex, G. R. A. Y., Deák, M., Casamayor, A., Downes, C. P., Cohen, P., Alessi, D. R., & Lucocq, J. M. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3370575 · Cited by 379
Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer
Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4114 · Cited by 369
Akt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Faber, A. C., Li, D., Song, Y., Liang, M.-C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., Maira, S.-M., García-Echeverría, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 319
Self-citationTolcher, A. W., Sarantopoulos, J., Patnaik, A., Papadopoulos, K., Lin, C.-C., Rodon, J., Murphy, B., Roth, B., McCaffery, I., Gorski, K. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6745 · Cited by 308
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Goel, A., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., Compton, C., Mayer, R. J., Bertagnolli, M. M., & Boland, C. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2401-2 · Cited by 302
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
Self-citationGarlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 274
A novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J. F., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 272
Kang, S., Denley, A., Vanhaesebroeck, B., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510772103 · Cited by 267
Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 245
Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase
Ueki, K., Yballe, C. M., Brachmann, S. M., Vicent, D., Watt, J. M., Kahn, C. R., & Cantley, L. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012581799 · Cited by 234
Promoter methylation of the PTEN gene is a common molecular change in breast cancer
García, J. M., Silva, J., Peña, C., Garcia, V., Rodríguez, R., Cruz, M. A., Cantos, B., Provencio, M., España, P., & Bonilla, F. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20062 · Cited by 224
Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218
Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A., & Eckhardt, S. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8168 · Cited by 216
Byun, D., Cho, K., Ryu, B., Lee, M., Park, J., Chae, K., Kim, H., & Chi, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.10962 · Cited by 184
Taniguchi, C. M., Tran, T. T., Kondo, T., Luo, J., Ueki, K., Cantley, L. C., & Kahn, C. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604628103 · Cited by 171
Lim, K.-H., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.014 · Cited by 159
Status of PI3K inhibition and biomarker development in cancer therapeutics
Markman, B., Atzori, F., Pérez-García, J., Tabernero, J., & Baselga, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp347 · Cited by 159
Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.
Han, S., Kato, H., Kato, S., Suzuki, T., Shibata, H., Ishii, S., Shiiba, K.-I., Matsuno, S., Kanamaru, R., & Ishioka, C. (2000) · PubMed · Cited by 158
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
Shoji, K., Oda, K., Nakagawa, S., Murayama-Hosokawa, S., Nagae, G., Uehara, Y., Sone, K., Miyamoto, Y., Hiraike, H., Hiraike-Wada, O., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605109 · Cited by 154
Ihle, N. T., Paine-Murrieta, G. D., Berggren, M. I., Baker, A. F., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., & Powis, G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0149 · Cited by 154
Luo, J., Sobkiw, C. L., Hirshman, M. F., Logsdon, M. N., Li, T. Q., Goodyear, L. J., & Cantley, L. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.003 · Cited by 138
Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas
Mizoguchi, M., Nutt, C. L., Mohapatra, G., & Louis, D. N. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00080.x · Cited by 136
Howes, A. L., Chiang, G. G., Lang, E. S., Ho, C., Powis, G., Vuori, K., & Abraham, R. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0698 · Cited by 135
Torbett, N. E., Luna-Moran, A., Knight, Z. A., Houk, A. R., Moasser, M. M., Weiss, W. A., Shokat, K. M., & Stokoe, D. (2008) · Biochemical Journal · doi:10.1042/bj20080639 · Cited by 134
Should individual PI3 kinase isoforms be targeted in cancer?
Jia, S., Roberts, T. M., & Zhao, J. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.007 · Cited by 120
Shekar, S. C., Wu, H., Fu, Z., Yip, S.-C., Nagajyothi, Cahill, S. M., Girvin, M. E., & Backer, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506005200 · Cited by 93
Wagner, L. M., Villablanca, J. G., Stewart, C. F., Crews, K. R., Groshen, S. G., Reynolds, C. P., Park, J. R., Maris, J. M., Hawkins, R. A., Daldrup-Link, H. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5918 · Cited by 78
Wagner, A. J., Hoff, D., LoRusso, P. M., Tibes, R., Mazina, K. E., Ware, J. A., Yan, Y., Derynck, M. K., & Demetri, G. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3501 · Cited by 66
Tolcher, A. W., Yap, T. A., Fearen, I., Taylor, A., Carpenter, C., Brunetto, A. T., Beeram, M., Papadopoulos, K. P., Yan, L., & Bono, J. S. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3503 · Cited by 64
Chen, J. S., Zhou, L. J., Entin‐Meer, M., Yang, X., Donker, M., Knight, Z. A., Weiss, W. A., Shokat, K. M., Haas-Kogan, D. A., & Stokoe, D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0393 · Cited by 63
Hickey, F. B., & Cotter, T. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511173200 · Cited by 55
Shapiro, G. I., Kwak, E. L., Baselga, J. M., Rodon, J. A., Scheffold, C., Laird, A., Bedell, C., & Edelman, G. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3500 · Cited by 45
Castaneda, C. P., Brandenburg, N. A., Bwire, R., Burton, G. H., & Zeldis, J. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.3737 · Cited by 43
LoRusso, P. M., Markman, B., Tabernero, J. M., Shazer, R. L., Nguyen, L. T., Heath, E. I., Patnaik, A., & Papadopoulos, K. P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3502 · Cited by 39
Between Utter Despair and Essential Hope
Renz, M., Koeberle, D., Cerny, T., & Strasser, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2203 · Cited by 20
The antiproliferative cytostatic effects of a self-activating viridin prodrug
Smith, A. E., Blois, J. T., Yuan, H., Aikawa, E. R., Ellson, C. D., Figueiredo, J., Weissleder, R., Köhler, R. H., Yaffe, M. B., Cantley, L. C., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1012 · Cited by 18
Flinn, I. W., Byrd, J. C., Furman, R. R., Brown, J. R., Lin, T. S., Bello, C., Giese, N. A., & Yu, A. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3543 · Cited by 18
Cited by
Lipid metabolic reprogramming in cancer cells
Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.49 · Cited by 1,398
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
“This has led to a major effort to develop inhibitors of PI3K, AKT, mTOR, and other components of the pathway (Courtney et al., 2010; Workman et al., 2010).”
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
Metadata
- Authors
- Courtney, K. D., Corcoran, R. B., & Engelman, J. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-20
- Volume
- 28
- Issue
- 6
- Pages
- 1075-1083
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2006771504
- Cited by
- 1,237
- References
- 108
- FWCI
- 40.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.